First 10 runs free
    First 10 runs free

    AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancer

    Resolved · regulation · Occurred · Assessed · 1 sources

    This assessment is dated 2026-09-29. Check what remains unresolved below before relying on it.

    Which companies' revenue or costs change?

    Regulatory submission initiates the FDA review clock, creating prospective milestone payments and royalty expansion for HUTCHMED and expanding AstraZeneca's oncology revenue base.

    QuestionWhat the evidence establishes
    What was reported?Reported factAstraZeneca submitted a New Drug Application (NDA) to the US FDA for ORPATHYS (savolitinib) combined with TAGRISSO (osimertinib).
    What else was confirmed?Reported factThe submission targets MET-driven, EGFR-mutated non-small cell lung cancer in patients who progressed following EGFR-TKI therapy.
    Does the valuation support acting?UnknownNo stored valuation assumptions for HCM yet — this is the next research task.
    What would change the assessment?UnknownFDA NDA acceptance and PDUFA date assignment — Official FDA notification of NDA filing acceptance and assignment of standard vs priority review status

    What would this event cost your holdings?

    Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.

    Test this event against my holdings

    Reported facts

    • · AstraZeneca submitted a New Drug Application (NDA) to the US FDA for ORPATHYS (savolitinib) combined with TAGRISSO (osimertinib).
    • · The submission targets MET-driven, EGFR-mutated non-small cell lung cancer in patients who progressed following EGFR-TKI therapy.
    • · The NDA filing is partnered with HUTCHMED, which co-developed savolitinib.

    Public research record

    Research framework · page evidence

    Completed event assessment

    milestone cash flows and US commercial royalty visibility on FDA regulatory advancement

    TypeClaimScope
    AssumptionAstraZeneca submitted a New Drug Application (NDA) to the US FDA for ORPATHYS (savolitinib) combined with TAGRISSO (osimertinib).2026-09-29
    Interpretationmilestone cash flows and US commercial royalty visibility on FDA regulatory advancementHCM
    Countercase, invalidators, and sources
    Countercase

    FDA grants Priority Review designation, accelerating US commercialization timeline to early 2027.

    What would change the view
    • · FDA NDA acceptance and PDUFA date assignment — Official FDA notification of NDA filing acceptance and assignment of standard vs priority review status
    • HUTCHMED Announces Submission of US NDA for ORPATHYS plus TAGRISSO · 2026-09-29

    Get the next source update

    One email when the underlying evidence changes. No daily digest.

    What remains unresolved

    Base path
    Standard 10-month PDUFA review timeline proceeds with advisory committee review scheduling.
    Adverse path
    FDA issues complete response letter requesting additional efficacy or biomarker stratification data.
    Supportive path
    FDA grants Priority Review designation, accelerating US commercialization timeline to early 2027.
    • · FDA NDA acceptance and PDUFA date assignment — Official FDA notification of NDA filing acceptance and assignment of standard vs priority review statusthis week

    Evidence

    • HUTCHMED Announces Submission of US NDA for ORPATHYS plus TAGRISSO2026-09-29

      “HUTCHMED announced that AstraZeneca has submitted a New Drug Application (NDA) to the FDA for ORPATHYS® (savolitinib) combined with TAGRISSO® (osimertinib) to treat patients with MET-driven EGFR-mutated non-small cell lung cancer.”

      Supports: AstraZeneca submitted US NDA to FDA for savolitinib plus osimertinib combo in MET-driven EGFR lung cancer